On October 8, 1958 the world's first pacemaker implantation was performed at the Karolinska Hospital in Stockholm, Sweden. The system had been developed by the surgeon A
• ke Senning and the physician inventor Rune Elmqvist. The patient was a 43-year-old engineer suffering from Stokes-Adams syndrome. His name was Arne H.W. Larsson ( Fig. 1) .
At the time Senning was in charge of the experimental laboratory at the newly inaugurated Department of Thoracic Surgery at the Karolinska Hospital in Stockholm. Elmqvist was head of the Electromedical Division at Elema Schönander in Stockholm. He had studied medicine in Lund, Sweden but had not pursued a medical practice. Rather, he had become a self-taught engineer. In 1931 he had designed the first portable optical electrocardiographic (ECG) recorder and in 1948 had introduced the well-known direct writing Mingograf ink jet recorders. When Senning and Elmqvist met in 1950 they began a close cooperation in the development and testing of fibrillators and defibrillators for use in conjunction with open heart surgery, then an experimental procedure. Senning had studied and been inspired by the experimental work of Bigelow and Callaghan 1,2 in stimulation for hypothermic cardiac standstill and Zoll who used external chest wall stimulation for management of Stokes-Adams attacks. 3, 4 During a visit to Minneapolis in 1957, Senning observed C.
Walton Lillehei during open heart surgery suture stainless steel electrodes to the ventricle to manage surgically caused atrioventricular (AV) block, after closure of a ventricular septal defect. The wires were led through the thoracic wall and connected to an external pulse generator. This method avoided the discomfort and placement problems in the postoperative patient associated with Zoll's external pacemaker. Senning considered this to be the beginning of the era of clinical pacing. 5, 6 On returning to Stockholm, Senning studied Lillehei's technique experimentally and clini-cally. While Earl Bakken (cofounder of Medtronic Inc., Minneapolis, MN, USA) manufactured an external, battery powered pacemaker for Lillehei, Elmqvist constructed one for Senning. However, there were major disadvantages with this technique: the inconvenience of carrying the pacemaker externally, the risk of connector damage and infection, and of local abscess formation possibly causing ascending infection and sepsis.
For Senning and Elmqvist, the solution was to implant the entire system. This was possible as new technology was becoming available making it possible to build a pacemaker small enough for subcutaneous implantation. In 1957 studies were initiated that included analysis of the electrical parameters of importance for clinical cardiac stimulation in patients by means of external pacemakers. 6 The first prototypes of implantable pacemakers were designed to provide impulses of about 2 V at a pulse duration of about 1.5 ms and a rate of 70-80 beats/min. 7 Newly available silicon transistors allowed the design of a stable and efficient blocking oscillator with small power consumption. The power source consisted of two sealed, encapsulated 60-mAh nickel-cadmium cells connected in series (Fig. 2) . These cells were recharged inductively once a month from a line-connected vacuum tube, radiofrequency generator (150 kHz). The current was transmitted by induction from an external flexible coil, placed overlying the implanted device. The wire leads that were to connect this pacemaker to the heart were hardwired to the pulse generator. The first pulse generators were truly handmade and encapsulated in Araldite epoxy resin produced by Ciba-Geigy. The approximate diameter and thickness became 55 and 16 mm, respectively, according to the dimensions of a shoe polish can from British Kiwi, which served as the mould! The leads used together with the first prototypes were twinned stainless steel wires with polyethylene insulation.
The First Implantation
In September 1958 Senning was contacted by Else Marie Larsson. Her husband, 43-year-old Arne HW Larsson, had been hospitalized for several months because of intermittent high grade AV block and multiple severe Stokes-Adams attacks occurring with increasing frequency. Bundle branch block had been noted as early as 1934 and intermittent bradycardia including syncope occurred for the first time in 1950. In 1956 his heart condition worsened, possibly due to hepatitis leading to a myocarditis exacerbating his preexistent intermittent complete AV block. Attempts at treatment included drug therapy like ephedrine, pentymal, atropine, isoproterenol, caffeine, and whisky though not all at the same time. The heart rate fluctuated between 60 and 70 per minute during which he felt well, down to 20 beats/min, all associated with variations in the degree of AV block. As often practiced at that time, digitalis was given in an attempt to convert the condition to permanent total AV block with the belief that a stable complete block would decrease the risk for StokesAdams attacks (Fig. 3) . This was ineffective and by the end of September 1958, the severity and incidence of Stokes-Adams attacks increased dramatically. He had to be resuscitated up to 30 times per day. His situation was considered hopeless.
Else Marie Larsson, having read press reports about ongoing experiments with electrical stimulation, pleaded with Dr. Senning to help her husband. A decision was made to implant a pacemaker as a more or less desperate rescue measure. Dr. Elmqvist rigged up circuits for two pacemakers and on October 8, 1958 Senning implanted two suture electrodes into the myocardium via a left-sided thoracotomy placing the Elmqvist pacemaker in the abdominal wall (Fig. 4) . This pacemaker controlled the heart rate for 3 hours and then suddenly stopped, probably damaged by electrocautery during the implantation procedure. The second unit was, therefore, implanted on the fol- (Fig. 6 ). The emission of stimuli continued at the preset rate for several weeks as long as recharging of the device was performed. In December 1958 it was decided to abandon pacemaker therapy but to leave the pulse generator in place awaiting the development of better leads. Larsson's heart rhythm still varied between different degrees of AV block but the Stokes-Adams attacks did not reoccur.
This first experience with a fully implantable pacemaker system was reported at the Second International Conference on Medical Electronics in 1959 and published as an abstract in 1960 (Fig. 7) . 8 Senning was convinced that better methods had to be found for long-term cardiac stimulation for management of AV block. 9 The steady rise PACE, Vol. 26
Figure 3. Electrocardiogram (ECG) from August 8, 1958 is showing atrioventricular (AV) block III, the ventricular rate is 30 beats/min and the atrial rate is 90 beats/min. Paper speed is 50 mm/s.
of the stimulation threshold associated with the stainless steel suture leads seen in temporary pacing after open heart surgery and the poor resistance against mechanical stress were limiting factors for permanent therapy. Better electrodes and leads had to be developed.
The Development Continues Elema Schönander together with the Telecom
Company, Ericsson, developed a new flexible lead in 1959. It consisted of four thin bands of stainless steel wound around a core of polyester braid and was insulated with soft polyethylene. Arne Larsson himself arranged for a forced stress test to be performed at the Royal Institute of Technology in Stockholm; a rather unique contribution from a patient to lead development. The test showed that the new lead resisted more than 184 million flex cycles and was predicted to last for at least 6 years in service. 10 A small platinum disc for epicardial placement, 8 mm in diameter and insulated on the back, served as the unipolar stimulating electrode. (Fig. 8) .
Elema Schönander began manufacture of pulse generators on a small scale and the Elema 135 rechargeable pacemaker was reported to have been successfully implanted in Stockholm 1959, 6 in Uruguay February 1960, 11 and in England March 1960. 12 At that time cardiac diagnostics were not advanced and the prevalence and clinical implications of intermittent bradycardia was not well established. This may explain why, Elema Schönander, a manufacturer of ECG recorders, did not appreciate the market potential of pacemaker therapy. Pacemakers were considered as an expensive service to prominent customers with little commercial value. The chances of obtaining a strong patent covering implantable heart stimulators were considered good. Nevertheless, the company never filed a patent application because of the perceived meager market prospects. The external charging system of this first model was too complicated, especially for elderly patients. Therefore, in 1960 Elmqvist constructed the Elema 137 pacemaker using Ruben-Mallory zincmercury-oxide cells as the power source, eliminating the need for periodic recharging.
The development that took place in Sweden in those years was not unique. The idea for the implantable pacemaker was "in the air" and the hunt was on for suitable devices, later to be known variously as "internal," "indwelling," "embeddable," "intracorporeal," or "implantable" pacemakers. In 1959, the engineer Wilson Greatbatch patented an implantable pacemaker, and William Chardack reported the first success with this unit powered by mercury cells in 1960. 13 Chardack used a two-stage surgical procedure with an initial lead positioning followed by the pulse generator implantation only after the stimulation threshold was considered stable, months following the lead implantation. In 1961, Zoll et al.
14 reported similar success with another model. As an alternative power source Glenn et al. 15 used radiofrequency transmission in the United States 1959 while Abrams et al. 16 in England used inductive coupling.
Continued Treatment of Arne Larsson
and third-degree AV block III. His average heart rate during the following 3 years was 35-40 beats/min during which his physical capacity was fairly good (Fig. 6) . However, the number of episodes of complete AV block with rates down to 20 beats/min lasting up to 3 weeks increased over time. During these periods his physical capacity decreased significantly, motivating him to ask for reestablishment of cardiac pacing (Fig. 9) . In November 1961 Senning performed a second left-sided anterior thoracotomy on Larsson for placement of three PACE, Vol. 26 epicardial leads. Two of the leads were placed on the cardiac apex and a third, spare lead, was sutured higher up on the left ventricle. The inactive Elmqvist pacemaker from 1958 was removed and replaced by an Elema 137 mercury-zinc (VOO) pulse generator (EM137) connected to two of the new leads. Stimulation was successful, but in January 1962 a gradual increase in stimulation rate to 115 beats/min after only 2 1 / 2 months in service warranted replacement of the pulse generator with another Elema 137. The continued story of Arne Larsson's pacemaker therapy much mirrors the incremental improvement in the early hardware and procedures of cardiac pacing. 17 Between October 1958 and December 2001, a total of 24 surgical interventions were performed on Arne Larsson. The indications for these interventions included battery depletion, lead fracture, high pacing rate, sudden loss of output, high pacing threshold, pressure necrosis in the pacemaker pocket, asynchronous rhythm interference problems, and some prophylactic device replacements (Table I) .
It later became clear that many of the device malfunctions were caused by iron contamination in the zinc anode of the Ruben-Mallory cells. The manufacturer had used iron balls in the mill where zinc was ground to the powder used in the anode. 20 used a long subcutaneous track for the wire after entering a jugular vein, reducing the risks for ascending infection and subsequent sepsis. The flexible Elema Schönander epicardial lead body was modified by replacement of the platinum disc electrode with a stainless steel tip, and later, improved by means of a platinum tip (Fig. 10) . In 1965 there were already reports on 305 European patients treated with implanted endocardial leads. 21 
Lead Technology

Arne Larsson Continued
In October 1967 Larsson experienced exit block associated with an increasing stimulation threshold (7-8 V) on the epicardial leads that had been implanted in 1961. As an emergency procedure, the old leads were exteriorized and connected transcutaneously to an external device and he was sent home to await implantation of a transvenous lead the following week. Before then Larsson had to be acutely readmitted due to recurrent exit block despite 10-V stimulation. A transvenous lead, the EMT 588 from Elema-Schönander was implanted via the right external jugular vein. In 1974, this lead functioned well for 81 months and was replaced by another EMT 588 lead because of exit block. This second 588 lead was implanted via the right internal jugular vein and functioned for more than 20 years until a rise in stimulation threshold warranted replacement in 1996. The final lead that he received was a Medtronic model 5023M implanted via the left cephalic vein (Fig. 11) . Over the years Arne Larsson had five lead systems and 22 pulse generators (Fig. 12) , including 11 different pacemaker models, as described in Table I . Between 1958 and 1974 he was paced in the VOO mode. In 1969 an upgrade to a VVI system was recommended. He declined, considering VOO devices to be more reliable. However, increasing discomfort due to interference between VOO stimulation and increasingly frequent ventricular ectopic beats finally motivated him to accept the recommended change to VVI in January 1974. In 1989 a decision was made to provide rate adaptive pacing, and a Medtronic Activitrax VVIR pulse generator was implanted as a replacement unit. From then until his death on December 28, 2001, Arne Larsson was paced in the VVIR mode. His last pacemaker was a Regency single chamber rate adaptive pacemaker from St. Jude Medical (Solna, Sweden). An upgrade to an atrial-tracking pacemaker was discussed during the 1960s but was never implemented, apparently due to recurrent atrial arrhythmias.
Concluding Remarks
The story of the first implantable pacemaker is one of courage and creativity by Drs. Rune 
Elmqvist and A
• ke Senning and both Arne HW and Else Marie Larsson. In retrospect, the risks these individuals took in 1958 with a completely unknown therapy were immense, but a lifesaving procedure was attempted on October 8, 1958 at the Karolinska Hospital. Rudimentary pacing technology advanced over the next few years mostly in the United States and, subsequently, in Europe through the efforts of skilled physicians and engineers. The early collaboration between engineers, physicians, and patients were the building blocks of a significant global medical industry. Zoll, one of the early pioneers in cardiac pacing, continued with the development of pacemakers for some years with Electrodyne, the company he had founded. Medtronic, Inc. (cofounded by Earl Bakken) started to produce and market the Chardack-Greatbatch pacemaker. Wilson Greatbatch still continues to be active and innovative. Until 1968, he was the primary technical consultant for Medtronic and subsequently founded Wilson Greatbatch, Ltd. (WGL). He convinced the pacing industry to switch from mercury to lithiumiodine cells. The company, Elema Schönander, for which Dr. Rune Elmqvist worked, subsequently became Siemens-Elema (Solna, Sweden) in 1974. In 1985 Siemens acquired Pacesetter Inc (Sylmar, CA, USA) combing the two organizations into their pacemaker division (Siemens-Pacesetter), which in 1994 was acquired by St. Jude Medical, to mention some of the companies involved in pacemaker therapy. 22 Rune Elmqvist continued his successful work as an engineer of outstanding creativity and innovative power. He received two honorary doctorates, in medicine and engineering, and also several international awards, among them the gold medal of the Swedish Royal Academy of Technological Science. Rune Elmqvist died in 1997 at age 90. In 1961 Ake Senning became Professor of Thoracic Surgery in Zurich. There, he actively stimulated the development of Thoracic Surgery in continental Europe where it had not been so well at the age of 86 of a malignancy totally unrelated to his conduction system disease or his pacemaker system. He will be remembered as the first human to receive an implanted pacemaker. He survived the engineer and the physician who together with their patient made medical history on October 8, 1958 . Arne Larsson will be remembered as the first human to receive an implanted pacemaker. To quote Arne's own words from his speech at the International Symposium on Progress in Clinical Pacing in Rome in December 2000, "what was done 1958 in Stockholm, with help of doctors Senning and Elmqvist -and in a small way, by myself -was a sensation. Today, you don't think of a pacemaker implantation as something sensational. Well, ladies and gentlemen, then you are all wrong. It is still a sensation -for the patient!"
